PDCD1 and melanoma: However, we succeeded to characterize lncRNA expression profiles to identify particularly PFS benefit of melanoma patients receiving anti-PD-1 monotherapyOur analyses provide also hints that this signature affects the response of melanoma patients treated with anti-PD-1 monotherapy by influencing immune-related pathways.